1. Cell Cycle/DNA Damage Apoptosis
  2. CDK Apoptosis
  3. 5,6-Dichlorobenzimidazole riboside

5,6-Dichlorobenzimidazole riboside  (Synonyms: DRB)

Cat. No.: HY-14392 Purity: 99.89%
Handling Instructions Technical Support

5,6-Dichlorobenzimidazole riboside (DRB) is a nucleoside analog that inhibits several carboxyl-terminal domain kinases, including casein kinase II and cell cycle-dependent kinases (CDK). 5, 6-dichlorobenzimidazole riboside has antitumor activity. 5, 6-dichlorobenzimidazole riboside can induce apoptosis.

For research use only. We do not sell to patients.

CAS No. : 53-85-0

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

Top Publications Citing Use of Products

    5,6-Dichlorobenzimidazole riboside purchased from MedChemExpress. Usage Cited in: J Extracell Vesicles. 2024 Aug;13(8):e12488.  [Abstract]

    PANC-1 EVs upregulated miR-31-5p levels in PSCs even under DRB (5,6-Dichlorobenzimidazole riboside, 10 μM) treatment.

    5,6-Dichlorobenzimidazole riboside purchased from MedChemExpress. Usage Cited in: Cell Rep. 2022 Oct 25;41(4):111546.  [Abstract]

    Transcription inhibitors does not affect heat-mediated E7 mRNA downregulation. CaSki (E) and SiHa (F) cells were pretreated with or without two transcription inhibitors, triptolide and DRB (5,6-Dichlorobenzimidazole riboside) for 60 min, and subjected to HT (42℃, 60 min). Relative expression levels of E7, HSP70 and β-Actin mRNAs were measured by RT-qPCR.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    5,6-Dichlorobenzimidazole riboside (DRB) is a nucleoside analog that inhibits several carboxyl-terminal domain kinases, including casein kinase II and cell cycle-dependent kinases (CDK). 5, 6-dichlorobenzimidazole riboside has antitumor activity. 5, 6-dichlorobenzimidazole riboside can induce apoptosis[1][2][3][4][5][6][7].

    Cellular Effect
    Cell Line Type Value Description References
    BSC-1 IC50
    30 μM
    Compound: 1f
    Antiviral activity against HSV-1 (herpes simplex virus), determined by ELISA in quadruplicate wells using BSC-1 cells
    Antiviral activity against HSV-1 (herpes simplex virus), determined by ELISA in quadruplicate wells using BSC-1 cells
    [PMID: 10882370]
    HCT-116 GI50
    25 μM
    Compound: DRB
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    [PMID: 22225635]
    HFF IC50
    24 μM
    Compound: 1f
    Visual cytotoxicity against stationary human foreskin fibroblasts (HFF) cells at the time of HCMV plaque enumeration
    Visual cytotoxicity against stationary human foreskin fibroblasts (HFF) cells at the time of HCMV plaque enumeration
    [PMID: 10882370]
    HFF IC50
    24 μM
    Compound: DRB
    Cytotoxicity against human foreskin fibroblasts (HFF) cells
    Cytotoxicity against human foreskin fibroblasts (HFF) cells
    10.1016/S0960-894X(00)80628-9
    HFF IC50
    24 μM
    Compound: DRB
    Compound was tested for visual cytotoxicity on human foreskin fibroblasts (HFF) cells
    Compound was tested for visual cytotoxicity on human foreskin fibroblasts (HFF) cells
    [PMID: 10882375]
    HFF IC50
    24 μM
    Compound: DRB
    Compound was evaluated for the visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration
    Compound was evaluated for the visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration
    [PMID: 7562945]
    HFF IC50
    24 μM
    Compound: DRB
    Tested for the visual cytotoxicity on HFF cells at the time of human cytomegalovirus (HCMV) plaque enumeration
    Tested for the visual cytotoxicity on HFF cells at the time of human cytomegalovirus (HCMV) plaque enumeration
    [PMID: 8071942]
    HFF IC50
    24 μM
    Compound: DRB
    Cytotoxicity produced in human foreskin fibroblasts (HFF) cells was estimated by visual scoring of cells unaffected by virus infection in the plaque-reduction assay.
    Cytotoxicity produced in human foreskin fibroblasts (HFF) cells was estimated by visual scoring of cells unaffected by virus infection in the plaque-reduction assay.
    [PMID: 8784445]
    HFF IC50
    42 μM
    Compound: 1f
    Antiviral activity against towne strain HCMV was determined by plaque reduction assay in duplicate wells using HFF cells
    Antiviral activity against towne strain HCMV was determined by plaque reduction assay in duplicate wells using HFF cells
    [PMID: 10882370]
    HFF IC50
    42 μM
    Compound: DRB
    Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells
    Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells
    [PMID: 10882375]
    Huh-7 CC50
    40.4 μM
    Compound: DRB
    Cytotoxicity against dual-reporter HCV replicon Huh7 cells by measuring XTT end points after 72 hrs
    Cytotoxicity against dual-reporter HCV replicon Huh7 cells by measuring XTT end points after 72 hrs
    [PMID: 17060518]
    Huh-7 CC50
    60.7 μM
    Compound: DRB
    Cytotoxicity against dual-reporter HCV replicon Huh7 cells by measuring FLuc reporter activity after 72 hrs
    Cytotoxicity against dual-reporter HCV replicon Huh7 cells by measuring FLuc reporter activity after 72 hrs
    [PMID: 17060518]
    Huh-7 EC50
    34.1 μM
    Compound: DRB
    Antiviral activity against HCV 1b con1 in dual-reporter HCV replicon Huh7 cells by measuring hRLuc reporter activity after 72 hrs
    Antiviral activity against HCV 1b con1 in dual-reporter HCV replicon Huh7 cells by measuring hRLuc reporter activity after 72 hrs
    [PMID: 17060518]
    KB IC50
    100 μM
    Compound: DRB
    The inhibition of KB cell growth was determined
    The inhibition of KB cell growth was determined
    [PMID: 8071942]
    KB IC50
    36 μM
    Compound: 1f
    Compound was tested for the inhibition of KB cell growth in quadruplicate wells
    Compound was tested for the inhibition of KB cell growth in quadruplicate wells
    [PMID: 10882370]
    KB IC50
    36 μM
    Compound: DRB
    Compound was evaluated for the inhibition of KB cell growth determined in quadruplicate assay
    Compound was evaluated for the inhibition of KB cell growth determined in quadruplicate assay
    [PMID: 7562945]
    KB IC50
    36 μM
    Compound: DRB
    Inhibitory activity against growth of human epidermoid oral carcinoma KB cell line
    Inhibitory activity against growth of human epidermoid oral carcinoma KB cell line
    [PMID: 8784445]
    LP-1 IC50
    29.81 μM
    Compound: DRB
    Cytotoxicity against human LP-1 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human LP-1 cells after 72 hrs by alamar blue assay
    [PMID: 15958589]
    MCF7 GI50
    36 μM
    Compound: DRB
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    [PMID: 22225635]
    NCI-H929 IC50
    20.13 μM
    Compound: DRB
    Cytotoxicity against human NCI-H929 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human NCI-H929 cells after 72 hrs by alamar blue assay
    [PMID: 15958589]
    OPM-2 IC50
    29.52 μM
    Compound: DRB
    Cytotoxicity against human OPM2 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human OPM2 cells after 72 hrs by alamar blue assay
    [PMID: 15958589]
    RPMI-8226 IC50
    46.79 μM
    Compound: DRB
    Cytotoxicity against human RPM18226 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human RPM18226 cells after 72 hrs by alamar blue assay
    [PMID: 15958589]
    U-266 IC50
    41.02 μM
    Compound: DRB
    Cytotoxicity against human U266 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human U266 cells after 72 hrs by alamar blue assay
    [PMID: 15958589]
    carcinoma cell line IC50
    36 μM
    Compound: DRB
    Compound was tested for inhibition activity of human oral carcinoma cell line (KB ) cells in quadruplicate assay.
    Compound was tested for inhibition activity of human oral carcinoma cell line (KB ) cells in quadruplicate assay.
    [PMID: 10882375]
    In Vitro

    5,6-Dichlorobenzimidazole riboside (10-80 μg/mL, 72 h) induces p53-dependent apoptosis of human colon cancer cells by blocking RNA synthesis[5].
    5,6-Dichlorobenzimidazole riboside (10-100 μM, 72 h) induces apoptosis of human MCF-7 breast cancer cells by regulating Mcl-1 and BclxL. And activates members of the caspase family in a time - and dose-dependent manner[6].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Western Blot Analysis[5]

    Cell Line: LS174T, HT29, SW48
    Concentration: 80 μg/mL
    Incubation Time: 24 h
    Result: Decreased incorporation of [5,6-3H] uridine and increased level of p53 protein.

    Cell Viability Assay[6]

    Cell Line: MCF-7, T-47D
    Concentration: 10, 50, 75,100 μM
    Incubation Time: 72 h
    Result: Inhibited cell-growth in a dose-dependent manner.
    Resulted in a higher early apoptotic population (5.7 ± 1.1 vs. 2 ± 0.4%) and late apoptotic population (15.9 ± 2.4 vs. 7.7 ± 0.9%) at a concentration of 75 μM.

    Western Blot Analysis[6]

    Cell Line: MCF-7
    Concentration: 75 μM
    Incubation Time: 0.5, 2, 6, 10 h
    Result: Reduced Mcl-1 protein levels in a time-dependent manner and increased the level of p53 after 6 h.
    In Vivo

    5,6-Dichlorobenzimidazole riboside (2.0-3.0 mg/0.25 mL water,  intraperitoneally injected twice a day for 5 days) does not inhibit the multiplication of the PR8 strain of influenza virus in mice[7].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    319.14

    Formula

    C12H12Cl2N2O4

    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=CC(Cl)=C(Cl)C=C3N=C2)O1

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMF : 100 mg/mL (313.34 mM; Need ultrasonic)

    DMSO : 100 mg/mL (313.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Ethanol : 7.69 mg/mL (24.10 mM; Need ultrasonic)

    H2O : < 0.1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.1334 mL 15.6671 mL 31.3342 mL
    5 mM 0.6267 mL 3.1334 mL 6.2668 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (7.83 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (7.83 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.95%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    Ethanol / DMF / DMSO 1 mM 3.1334 mL 15.6671 mL 31.3342 mL 78.3355 mL
    5 mM 0.6267 mL 3.1334 mL 6.2668 mL 15.6671 mL
    10 mM 0.3133 mL 1.5667 mL 3.1334 mL 7.8336 mL
    15 mM 0.2089 mL 1.0445 mL 2.0889 mL 5.2224 mL
    20 mM 0.1567 mL 0.7834 mL 1.5667 mL 3.9168 mL
    DMF / DMSO 25 mM 0.1253 mL 0.6267 mL 1.2534 mL 3.1334 mL
    30 mM 0.1044 mL 0.5222 mL 1.0445 mL 2.6112 mL
    40 mM 0.0783 mL 0.3917 mL 0.7834 mL 1.9584 mL
    50 mM 0.0627 mL 0.3133 mL 0.6267 mL 1.5667 mL
    60 mM 0.0522 mL 0.2611 mL 0.5222 mL 1.3056 mL
    80 mM 0.0392 mL 0.1958 mL 0.3917 mL 0.9792 mL
    100 mM 0.0313 mL 0.1567 mL 0.3133 mL 0.7834 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Requested Quantity *

    Applicant Name *

     

    Salutation

    Email Address *

     

    Phone Number *

    Department

     

    Organization Name *

    City

    State

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    5,6-Dichlorobenzimidazole riboside
    Cat. No.:
    HY-14392
    Quantity:
    MCE Japan Authorized Agent: